APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg £31
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg £91
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  2. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  3. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  4. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  5. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  6. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  7. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  8. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  9. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  10. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  11. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  12. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  13. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  14. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  15. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  16. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  17. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  18. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  19. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  20. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  21. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  22. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  23. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  24. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  25. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  26. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  27. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  28. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  29. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  30. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  31. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  32. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  33. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  34. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  35. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  36. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  37. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  38. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  39. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  40. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  41. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  42. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  43. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  44. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  45. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  46. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  47. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  48. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  49. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  50. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  51. Sheng J, et al. 2021. eLife. 10:00. PubMed
  52. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  53. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  54. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  55. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  56. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  57. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  58. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  59. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  60. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  61. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  62. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  63. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  64. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  65. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  66. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  67. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  68. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  69. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  70. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  71. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  72. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  73. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  74. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  75. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  76. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  77. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  78. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  79. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  80. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  81. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  82. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  83. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  84. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  85. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  86. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  87. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  88. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  89. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  90. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  91. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  92. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  93. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  94. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  95. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  96. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  97. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  98. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  99. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  100. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  101. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  102. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  103. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  104. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  105. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  106. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  107. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  108. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  109. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  110. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  111. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  112. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  113. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  114. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  115. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  116. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  117. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  118. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  119. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  120. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  121. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  122. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  123. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  124. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  125. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  126. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  127. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  128. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  129. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  130. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  131. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  132. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  133. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  134. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  135. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  136. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  137. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  138. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  139. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  140. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  141. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  142. Harty J 2009. Infect Immun. 77:1894. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse IFN-γ

  • Biotin anti-mouse IFN-γ

  • FITC anti-mouse IFN-γ

  • PE anti-mouse IFN-γ

  • Purified anti-mouse IFN-γ

  • Alexa Fluor® 488 anti-mouse IFN-γ

  • Alexa Fluor® 647 anti-mouse IFN-γ

  • Pacific Blue™ anti-mouse IFN-γ

  • PerCP/Cyanine5.5 anti-mouse IFN-γ

  • PE/Cyanine7 anti-mouse IFN-γ

  • Brilliant Violet 421™ anti-mouse IFN-γ

  • Brilliant Violet 650™ anti-mouse IFN-γ

  • Ultra-LEAF™ Purified anti-mouse IFN-γ

  • Brilliant Violet 711™ anti-mouse IFN-γ

  • Brilliant Violet 785™ anti-mouse IFN-γ

  • Brilliant Violet 605™ anti-mouse IFN-γ

  • Brilliant Violet 510™ anti-mouse IFN-γ

  • Purified anti-mouse IFN-γ (Maxpar® Ready)

  • PE/Dazzle™ 594 anti-mouse IFN-γ

  • Alexa Fluor® 700 anti-mouse IFN-γ

  • APC/Cyanine7 anti-mouse IFN-γ

  • GoInVivo™ Purified anti-mouse IFN-γ

  • APC/Fire™ 750 anti-mouse IFN-γ

  • Spark NIR™ 685 anti-mouse IFN-γ

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account